Novo Nordisk Pharmatech has entered an agreement with Signet Chemical Corporation for the distribution of its pharmaceutical range of quaternary ammonium compounds (FEF® Quats) to the healthcare industry in India, Bangladesh and Sri Lanka.
Managing director of Signet Mr Harish Shah commented on this new collaboration: “We are pleased to be associated with Novo Nordisk Pharmatech, which is the leading supplier of Quats to the pharmaceutical and biopharmaceutical markets. Novo Nordisk Pharmatech’s FeF® Quats complement our existing portfolio of excipients used especially for ophthalmic, nasal and topical dosage forms”.
Novo Nordisk Pharmatech manufactures Quats, including benzalkonium chloride, cetrimide and cetyl trimethyl ammonium Bromide (CTAB). They are available in customised grade and meet current good manufacturing practice (cGMP) International Conference on Harmonisation (ICH) Q7 for active pharmaceutical ingredients (API), which is the highest available quality standard.
The company’s products comply with the latest pharmacopoeial standards and are extensively supported by Certificate of Suitability of Monographs of the European Pharmacopoeia (CEP), drug master files (DMF) and a comprehensive package of regulatory and quality assurance documents. Its manufacturing site in Koege, Denmark, is audited by the Danish Medicines Agency and the US Food and Drug Administration (FDA).
Sales and marketing director at Novo Nordisk Pharmatech Steve Profit says: “We are very happy to work with Signet as our distribution partner for pharmaceuticals. Novo Nordisk Pharmatech’s FeF® Quats products fit perfectly with Signet’s wide range of excipients enabling the customers to take advantage of these synergies.
“We wish to give the best service to our customers and the local pharma team of Signet are experts in working with customers to support their product development.”
Signet is a pharmaceutical excipient distributor company in India offering a broad range of excipients. Founded in 1986, the Signet Chemical Corporation is a pioneer in the excipients business in India.
Since its inception, Signet has combined technical expertise with commercial support to provide its clients with accurate information and high product value. With 95 qualified members, the Signet team has an excellent understanding of the intricacies of the market and has strong relationships with key partners to take the company forward.
Signet has a turnover of approximately $174m and around 100 employees serving India, Bangladesh, Nepal and Sri Lanka.
For more information, please visit: www.novonordiskpharmatech.com.